Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

20141,896 citationsJournal Articlebronze Open Access

Authors

Martyn Caplin · UCL Australia

Marianne Pavel · Charité - Universitätsmedizin Berlin

Jarosław B. Ćwikła · University of Warmia and Mazury in Olsztyn

Alexandria T. Phan

Markus Raderer · Medical University of Vienna

Eva Sedláčková · Charles University

Guillaume Cadiot · Hôpital Robert-Debré

Abstract

Lanreotide was associated with significantly prolonged progression-free survival among patients with metastatic enteropancreatic neuroendocrine tumors of grade 1 or 2 (Ki-67 <10%). (Funded by Ipsen; CLARINET ClinicalTrials.gov number, NCT00353496; EudraCT 2005-004904-35.).

Topics & Keywords

Neuroendocrine Tumor Research Advances Neuroblastoma Research and Treatments Lung Cancer Research Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 371, Issue 3, pp. 224-233

DOI: 10.1056/nejmoa1316158

Field-Weighted Citation Impact: 105.64